PAK6 (Ser-165), Phosphospecific Antibody

Product Specifications

Background

P21-activated kinase 6 (PAK6) is a member of the PAK family of serine/threonine kinases. These kinases have a highly conserved amino-terminal Cdc42/Rac interactive binding domain and a carboxyl-terminal kinase domain. PAK kinases are implicated in the regulation of a number of cellular processes, including cytoskeleton rearrangement, apoptosis and the MAP kinase signaling pathway. PAK6 interacts with the androgen receptor, a steroid hormone transcription factor involved in male sexual differentiation and development. PAK6 is highly expressed in testis and prostate tissues. Regulation of PAK6 kinase activity occurs through multiple sites of phosphorylation. Activation of PAK6 requires autophosphorylation of Ser-560 and MKK-6 induced phosphorylation of Tyr-566. In addition, p38 MAPK can phosphorylate Ser-165, which increases PAK6 kinase activity. Thus, multiple signaling pathways may regulate the activity of PAK6 through differential phosphorylation.

Synonyms

P21, PAK

Swiss Prot

Q9NQU5

Modification Site

Ser-165

Host

Rabbit

Cross Reactivity

Human

Target

PAK6 (Ser-165)

Clonality

Polyclonal

Isotype

IgG

Conjugation

Unconjugated

Source

PAK6 (Ser-165) synthetic peptide (coupled to carrier protein) corresponding to amino acids around serine 165 in human PAK6.

Applications

Purification

Antigen Affinity purification

Dilution

WB (1:300-5000)

Buffer

PBS + 1 mg/ml BSA, 0.05% NaN3 and 50% glycerol

Modification

Phosphorylation

Storage Conditions

Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C.

Specificity

This antibody was cross-adsorbed to unphosphorylated PAK6 (Ser-165) peptide then Affinity purification using phospho-PAK6 (Ser-165) peptide. The antibody detects a 75 kDa* band on SDS-PAGE immunoblots of human PAK6 recombinant protein phosphorylated with ERK2. This reactivity is specifically blocked by pre-incubation with phospho-PAK6 (Ser-165) peptide and also by treatment with lambda phosphatase. The sequence used has two amino acid differences compared to rat and mouse PAK6.